New drug PEEL-224 enters first human tests for advanced cancers
NCT ID NCT05329103
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PEEL-224 (a drug given by infusion) and FOLF+B (a combination of chemotherapy drugs and bevacizumab)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, first-in-human study with only 65 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at Pennsylvania Hospital
COMPLETEDPhiladelphia, Pennsylvania, 19106, United States
-
Carolina BioOncology Institute
COMPLETEDHuntersville, North Carolina, 28078, United States
-
HonorHealth Research Institiute
RECRUITINGScottsdale, Arizona, 85258, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mary Crowley Cancer Research
COMPLETEDDallas, Texas, 75230, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Center
ACTIVE_NOT_RECRUITINGPalo Alto, California, 94305, United States